Decanoic acid, also called capric acid, is a straight-chain C10 fatty acid better known for lipid and nutrition research than for being a high-impact aroma constituent. In the AromaForge archive it appears as a minor component in cognac-white style distillates and related materials, while the broader live literature is strongest on identity, fragrance safety review, and medium-chain-fatty-acid pharmacology. Public evidence supports a modern RIFM safety assessment and a real mechanistic epilepsy literature involving AMPA-receptor inhibition, but those findings come from nutritional or pharmacology contexts rather than essential-oil use and should not be converted into medical claims.
Chemical identity and composition
PubChem identifies decanoic acid as a C10 straight-chain saturated fatty acid commonly called capric acid. Archive occurrence is relatively sparse compared with more odor-active terpenes and aldehydes; when present, it reads more as a fatty distillation or fermentation-linked support constituent than a defining fragrance note.
Aroma and practical use
- Use the recorded fatty, goaty, waxy, rancid, soapy descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
RIFM's safety assessment concluded that decanoic acid was not expected to be genotoxic, was not a concern for skin sensitization at declared use levels, and was not expected to be phototoxic or photoallergenic.
The published PDF summarizes favorable fragrance-safety conclusions across multiple toxicology endpoints, supported partly by read-across.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
The same RIFM assessment listed a repeated-dose NOAEL of 333.33 mg/kg/day and a reproductive-toxicity NOAEL of 1000 mg/kg/day under its assessment logic.
Those values are stated in the human-health summary and supported by read-across discussion in the full document.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
A Brain study reported seizure-control effects of decanoic acid through direct AMPA receptor inhibition, supporting a distinct mechanistic role for decanoic acid in MCT-diet epilepsy research.
The paper title and accessible full-text record directly frame decanoic acid as an active mediator rather than an inert dietary byproduct.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
For AromaForge purposes, the fragrance-safety review is more directly relevant than the epilepsy literature because the latter reflects nutritional and pharmacologic exposure contexts.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
RIFM concluded decanoic acid did not present a concern for skin sensitization at current declared fragrance use levels.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
No claim should imply that trace aromatic exposure to decanoic acid reproduces the dosing context used in medium-chain triglyceride or epilepsy studies.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
Terpinen-4-olAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
mixed · effect
No source citation attached.
Read Terpinen-4-ol report →How the effects were investigated
direct AMPA receptor inhibition
Primary epilepsy research reported seizure-control effects linked to direct inhibition of AMPA receptors by decanoic acid, distinguishing it from ketone-only explanations of the MCT diet.
This experimental finding does not establish benefit, dose or safety in people using this blend.
medium-chain-fatty-acid metabolic signaling
Decanoic acid is handled as a medium-chain fatty acid in metabolic literature, but this broader biochemical context should not be overstated as a fragrance-constituent mechanism.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (8)
- Archive occurrence data for decanoic acid are thinner than for more classic terpene constituents.
- The strongest mechanistic literature for decanoic acid comes from diet and neuropharmacology rather than essential-oil exposure models.
- This research pass did not verify a rich constituent-specific aroma-study literature beyond identity and safety sources.
- sensitizing set to false (2026-07-11) based on the already-cited RIFM fragrance safety assessment (rifm-decanoic-acid-2020), which explicitly concluded decanoic acid was not a concern for skin sensitization at declared fragrance use levels; no numeric IFRA/EU Annex III dermal percentage limit was located, so dermal_limit_verified remains false.
- Worker c8 verification (2026-07-13): RIFM 2020 safety assessment located and reviewed (doi.org/10.1016/j.fct.2020.111465). Confirms not a skin sensitization concern and not expected to be phototoxic/photoallergenic (UV/Vis spectra, no significant absorbance 290-700nm). No RIFM/IFRA leave-on percentage restriction table exists for decanoic acid since sensitization was not identified as a driver; prior dermal_limit_pct:25 was an unsourced placeholder and has been corrected to null rather than implying a false restriction ceiling.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.